Inspire Medical Systems, Inc. INSP
70.50
1.69
2.46%
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 15.1×
Follow INSP
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
9.57 | 11.39 | 18.37 | 49.47 |
+8 more quarters Free account |
P/S ratio |
1.43 | 1.62 | 2.97 | 2.47 | |
P/FCF ratio |
10.99 | 15.31 | 34.52 | 22.02 | |
P/Operating CF |
55.38 | 115.21 | 51.62 | 31.76 | |
P/B ratio |
1.56 | 1.87 | 3.47 | 3.27 | |
Price to Tangible BV |
1.56 | 1.87 | 3.47 | 3.27 | |
EV/Sales |
1.10 | 1.33 | 2.66 | 2.13 | |
EV/EBITDA |
14.15 | 18.69 | 39.11 | 41.49 | |
EV/Operating CF |
6.31 | 8.95 | 20.74 | 14.06 | |
EV/FCF |
8.46 | 12.63 | 30.91 | 19.01 | |
Quick Ratio |
5.96 | 4.35 | 4.46 | 3.88 | |
Current Ratio |
8.55 | 6.34 | 6.08 | 5.29 | |
Net Debt/EBITDA |
(83.38) | (76.67) | (6.22) | (24.95) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.04 | 1.11 | 1.06 | 1.10 | |
Operating CF/Net income |
73.97 | (1.14) | 0.39 | 6.90 | |
Capex/Depreciation |
(2.10) | (2.02) | (3.09) | (3.18) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.31% | 12.62% | 9.27% | 10.78% | |
Selling, General and Administrative Expense of Revenue |
73.42% | 74.40% | 60.19% | 70.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.57% | 15.00% | 10.41% | 13.13% | |
Graham Net Nets |
0.40 | 0.30 | 0.17 | 0.20 | |
Graham Number |
54.79 | 53.05 | 54.81 | 27.69 | |
Earnings Yield |
10.45% | 8.78% | 5.44% | 2.02% | |
Free Cash Flow Yield |
9.10% | 6.53% | 2.90% | 4.54% | |
Revenue per Share |
6.96 | 7.13 | 9.16 | 7.65 | |
Operating CF per Share |
0.81 | 0.45 | 1.79 | 2.34 | |
Capex per Share |
(0.32) | (0.34) | (0.36) | (0.36) | |
Free Cash Flow per Share |
0.49 | 0.11 | 1.42 | 1.98 | |
Cash per Share |
11.12 | 9.89 | 10.50 | 11.00 | |
Shareholders Equity per Share |
28.63 | 27.61 | 26.60 | 22.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.63 | 27.61 | 26.60 | 22.72 | |
Free Cash Flow |
14.07 | 3.12 | 41.81 | 58.09 | |
Working Capital |
537.49 | 477.40 | 487.60 | 475.65 | |
Capital Expenditures |
(9.16) | (9.73) | (10.66) | (10.44) | |
Net Current Asset Value |
508.26 | 447.78 | 457.50 | 445.23 | |
EV/EBIT |
18.31 | 23.81 | 47.60 | 51.16 | |
Capex to Sales |
0.05 | 0.05 | 0.04 | 0.05 | |
Net Profit Margin |
0.16% | (5.52%) | 50.58% | 4.42% | |
Price to Operating Income |
23.77 | 28.85 | 53.16 | 59.26 | |
| Other line items | |||||
Average Receivables |
120.51 | 98.86 | 106.38 | 98.87 | |
Average Payables |
40.13 | 35.49 | 37.63 | 47.08 | |
Average Inventory |
146.04 | 132.98 | 112.71 | 104.60 | |
Average Assets |
864.09 | 821.09 | 857.85 | 801.96 | |
Average Common Equity |
751.70 | 714.04 | 735.43 | 681.51 |
Columns are period end dates